MP
DMAA

Mangrove Partners’s Drugs Made In America Acquisition Corp DMAA Stock Holding History

Mangrove Partners’s Portfolio DMAA Stock Details DMAA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-350,000
Closed -$3.57M – 254
2025
Q2 		$3.57M Hold
350,000
– – 0.38% 44
2025
Q1 		$3.51M Buy
+350,000
New +$3.5M 0.38% 47

Other funds holding DMAA

KIM
Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 22.54% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mangrove Partners's DMAA Position: Q3 2025 in Review

Mangrove Partners sold out of Drugs Made In America Acquisition Corp (DMAA) in Q3 2025, closing a stake of 350,000 shares — an estimated $3.57M sold.

Mangrove Partners first reported a position in DMAA in Q1 2025 and held it in 2 quarters. The position peaked at $3.57M in Q2 2025. 37 funds tracked by Wall St. Rank hold DMAA as of Q3 2025.

  • Mangrove Partners reported no remaining Drugs Made In America Acquisition Corp position as of Q3 2025 after selling out during the quarter.
  • Mangrove Partners sold 350,000 Drugs Made In America Acquisition Corp shares in Q3 2025, an estimated $3.57M.
  • Mangrove Partners first reported a position in Drugs Made In America Acquisition Corp in Q1 2025 and held it in 2 quarters.
  • Mangrove Partners's Drugs Made In America Acquisition Corp position peaked at $3.57M in Q2 2025.
  • 37 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp as of Q3 2025.

Based on Mangrove Partners's 13F filing for Q3 2025, filed 14 Nov 2025.